In the reperfusion era thrombolytic trials reported a "smoker's paradox" in which a favorable clinical outcome was noted in smokers. This was thought to be due in part to the hypercoagulable state with smoking, resulting in a more thrombotic coronary occlusion which responds well to thrombolysis. To determine whether the type of reperfusion strategy affects outcome in smokers vs. nonsmokers, we evaluated 395 patients (pts) who were randomized to tPA vs. primary PTCA in the PAMI study of whom 168 were smokers (SM) and 128 never smoked INS). The combined in-hospital outcome including death, recurrent MI or recurrent ischemia was similar in SM and NS (p = 0.12) despite univariate analysis revealing that SM were younger (65 vs. 55 yrs, p < 0.001) and less likely to be female (20 vs. 41%, P < 0.001) compared with NS. Stratifying the data according to reperfusion modality, smokers treated with tPA did significantly better than NS (p = 0.041; a difference that did not exist in the PTCA group (SM vs NS, p = 0.69). Multivariate analysis revealed that NS treated with PTCA had less recurrent ischemia (11 vs. 33%, p~0.004) and combined mortality or recurrent MI (7 vs 18%, P = 0.05) compared with those treated with tPA. At 6 months, NS treated with PTCA vs. tPA continued to have fewer deaths or recurrent MI. (11 vs. 24%, P = 0.07). Conversely, treatment strategy in SM did not significantly affect hospital outcomes; recurrent ischemia (12 vs. 23%, P = 0.07) and mortality combined with recurrent MI (6 vs. 8%, P = 0.55) in PTCA and tPA groups. The statistical significance of these associations is maintained when controlling for age and gender.
The most common reason for not treating with n was absence of criteria for ST elevation MI in 179/222 pts 181 %). Of 35/222 (16%) who presented between 4-12 hrs, age or duration of symptoms was the sole contraindication to n in only 8 (4%). Other less common major contra indications to TT included prolonged chest massage, recent surgery, active internal bleeding, and hemodynamic instability. Conclusions: 1) Most pts did not receive n.
2) Even with expanded treatment criteria, few additional pts become candidates for n. 3) Future research should focus on the majority of the MI population which fails to meet ECG or other n criteria.
Thrombolytic therapy In) clearly saves lives in acute myocardial infarction IMI). but the major limitation to its widespread use has been the large proportion of M I pts considered ineligible for n. In recent overviews of the large randomized n trials, net benefit is consistently seen with: 1) ST elevation Mlldiagnostic ST elevations in any anatomic location) or left bundle branch block on presenting ECG; 2) any age; and 3) onset of symptoms < 12 hrs. To describe correlates of n utilization and to determine the potential impact of recently expanded n criteria on the number of untreated pts, we studied 292 pts with acute MI who were admitted via the Emergency Department between June 1991 and December 1992 into a large university teaching hospital.
Results: 222 (76%) did not receive n. Univariate correlates of n utilization: We also instituted this AMI team approach in three area small town rural hospitals to see if this approach would be beneficial in this setting. Similar reductions in time to treatment were observed.
Eligibility for Thrombolytic Therapy is Limited Even with Expanded Criteria

Conclusion: 1) AMI team approach effectively lowers time to treatment
in large medical center hospitals and in small town rural hospitals; 2) widespread use of this concept could significant lower mortality from ST segment elevation AMI in the United States.
vs. other) was the only variable predicting mortality. Age was not a predictive factor using univariate analysis; using multivariate analysis there was a trend towards increasing mortality with age, which did not reach statistical significance. We conclude advanced age is not invariably associated with a fatal outcome in acute infarction patients with cardiogenic shock and encourage consideration of infarct angioplasty in patients presenting with shock regardless of patient age.
Stephen L. Kopecky, Martha J. Siska, Jean A. Jurek, Stephen F. Gudgell, Thomas D. Meloy, Deborah R. Fischer, Guy S. Reeder. Mayo Clinic, Rochester, MN In the United States, the average time between a patient's arrival in the emergency room (ER) and the administration of thrombolytic therapy for ST elevation and acute myocardial infarction (AMI) is over one hour. If the time to treatment (Rx) after arrival in the ER could be reduced by 30 minutes, it has been estimated that at least 5,000 lives could be saved annually in the United States. In our institution, the average time to Rx after arrival in the ER for ST elevation AMI from June 1991 to June 1993 was 71 ± 32 minutes Imedian 64 minutes). We then developed an "AMI team" approach which included ER physicians, ER nurses, ECG technicians, and pharmacists. The diagnostic approach of the AMI team was based on two pocket cards that contained information on the following: 1) indicationslcontraindications of thrombolytic treatment in AMI; 2) thrombolytic treatment drug selection guidelines ItPA versus SK); 31 ancillary therapy drugs and dosages; and 4) ancillary therapy indications/contraindications. Treatment by the AMI team centered around an AMI kit-a tackle box that contained both thrombolytic drugs, all necessary ancillary treatments (ASA. heparin, beta blockers, nitrates, MS, and magnesium) and IVtubing plus drug compatibility charts The time to Rx before and after institution of the AMI team was as follows:
Patients (pts) with acute myocardial infarction (AMII ineligible for thrombolytic therapy (TTX) are at increased risk. Invasive coronary procedures (ICP) have been recommended for these pts. In 3 surveys performed in the CCU's of Israel during 1990, '92 and ' Angioplasty or thrombolysis (T) during acute myocardial infarction (MI) are two effective methods for achieving reperfusion, but whether reperfusion induced by angioplasty confers the same protection against the presence of late potentials on signal-averaged electrocardiography (SAE) as that induced by T remains debated. We studied retrospectively 102 consecutive Pts with successful reperfusion (TIMI grade 3 patency in acute phase), obtained by T, primary angioplasty (P), or rescue angioplasty (R) during the first 6 hours of MI. T Pts all had angiography at 90 min to prove reperfusion. All had SAE > 6 days later. Late potentials were defined as ,=:2 of the following criteria: QRS > 120 msec, RMS40 < 20 f1.v, LAS> 38 msec. Results are (mean ± SD):
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Clinical trials to determine the efficacy of thrombolytic therapy trials consider all patients with acute inferior myocardial infarction (IMI) as a single group, but these patients have heterogeneous clinical characteristics. Stratification of IMI patients by the amount of myocardium at risk and the time to treatment should clarify the precise indications for thrombolytic therapy. This study is an independent secondary analysis of the TIMI II patient data available through the NHLBI. Clinical features were used to identify IMI subgroups in the TIMI II trial characterized by increased myocardium at risk. There were 861 patients with IMI who had one or more of the following markers for myocardium at risk: anterior ST depression, hypotension defined as a systolic blood pressure < 100 mmHg, or advanced AV block. There were 455 patients with IMI who did not have any markers of increased myocardium at risk. The subgroups for each marker and the group without any marker were then stratified by time to thrombolysis and their outcomes were compared to historical controls with hypothesis tests and confidence intervals.
Patients with IMI plus anterior ST depression, hypotension, or AV block who received thrombolysis had a highly statistically significant decre,1se in mortality (p < 0.001) compared to historical controls. Patients with IMI plus hypotension or AV block had a significant decrease in mortality only up to 3 hours from onset of symptoms (p < 0.05). In patients with simple 1M I, an insignificant relative reduction in mortality of 15.4% was seen from a baseline mortality of 2.5%. Consequently, thrombolytic therapy cannot be justified for all patients with IMI, but it is clearly indicated for IMI with anterior ST depression, advanced AV block, and hypotension. The decrease in mortality for patients with hypotension or AV block declines steeply over the first 3 hours. IMI with anterior or lateral ST elevation, right ventricular infarction, or new bundle-branch block is hypothesized to have the same benefit but could not be tested because the data was not available in the TIMI II database. To demonstrate significance of the relative reduction in mortality for patients with simple IMI would require 32,220 patients. For the individual patient with a simple inferior myocardial infarction, the essentially immaterial benefit of 15.4% relative reduction in mortality from a baseline mortality of 2.5% may not outweigh the risk of a hemorrhagic complication of therapy. In conclusion, IMI patients should be considered on an individual basis, with consideration given to the amount of myocardium at risk and the time to treatment. Thus, after MI, the prevalence of late potentials appears lower when acute reperfusion is obtained by angioplasty rather than by thrombolysis. This difference does not appear related to differences in time to treatment, time to reperfusion, left ventricular function or other patient characteristics.
